This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Ablynx NV
Ablynx NV, a pioneering biopharmaceutical company headquartered in Belgium, focuses on the development of innovative therapies based on its proprietary Nanobody technology. Founded in 2001, Ablynx has made significant strides in the biotechnology sector, particularly in the fields of immunology and oncology. The company’s core offerings include a range of Nanobody-based therapeutics, which are unique due to their small size and ability to target specific proteins with high precision. This innovative approach has positioned Ablynx as a leader in the biopharmaceutical industry, with notable achievements including successful partnerships and advancements in clinical trials. With a strong presence in Europe and expanding operations globally, Ablynx continues to drive forward in the quest for transformative medical solutions.
DitchCarbon Score
How does Ablynx NV's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ablynx NV's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ablynx NV, headquartered in Belgium (BE), currently does not report specific carbon emissions data, as no figures are available for the most recent year. The company is a current subsidiary of Sanofi, and any climate commitments or emissions data may be inherited from its parent organisation. Ablynx NV has not outlined specific reduction targets or initiatives in its own right. However, it is important to note that it may align with the climate strategies and targets set by Sanofi, which include commitments to the Science Based Targets initiative (SBTi) and participation in various climate-related initiatives such as CDP, RE100, and the Race to Zero campaign. As a subsidiary, Ablynx NV's climate commitments may reflect the broader sustainability goals of Sanofi, which aims to reduce its overall carbon footprint and enhance environmental stewardship. For detailed emissions data and specific reduction targets, stakeholders are encouraged to refer to Sanofi's sustainability reports and disclosures.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ablynx NV is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
